TY - JOUR
T1 - Superior intellectual outcomes after proton radiotherapy compared with photon radiotherapy for pediatric medulloblastoma
AU - Kahalley, Lisa S.
AU - Peterson, Rachel
AU - Ris, M. Douglas
AU - Janzen, Laura
AU - Okcu, M. Fatih
AU - Grosshans, David R.
AU - Ramaswamy, Vijay
AU - Paulino, Arnold C.
AU - Hodgson, David
AU - Mahajan, Anita
AU - Tsang, Derek S.
AU - Laperriere, Normand
AU - Whitehead, William E.
AU - Dauser, Robert C.
AU - Taylor, Michael D.
AU - Conklin, Heather M.
AU - Chintagumpala, Murali
AU - Bouffet, Eric
AU - Mabbott, Donald
N1 - Funding Information:
Supported by the National Institutes of Health/National Cancer Institute (R01CA187202 and K07CA157923 to L.S.K.) and the Canadian Institute of Health Research (MOP-123537 to D.M.).
Publisher Copyright:
© 2019 by American Society of Clinical Oncology
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/2/10
Y1 - 2020/2/10
N2 - PURPOSE Proton radiotherapy (PRT) may lessen the neuropsychological risk traditionally associated with cranial radiotherapy for the treatment of pediatric brain tumors by reducing the dose to normal tissue compared with that of photon radiotherapy (XRT). We examined the change in intellectual scores over time in patients with pediatric medulloblastoma treated with craniospinal PRT versus XRT. METHODS Intelligence test scores were obtained for a sample of pediatric patients treated between 2007 and 2018 on the same medulloblastoma protocols that differed only in radiotherapy modality (PRT v XRT). Growth curve analyses compared change in scores over time since diagnosis between groups. RESULTS Longitudinal intelligence data from 79 patients (37 PRT, 42 XRT) were examined. Groups were similar on most demographic/clinical variables, including sex (67.1% male), age at diagnosis (mean, 8.6 years), craniospinal irradiation dose (median, 23.4 Gy), length of follow-up (mean, 4.3 years), and parental education (mean, 14.3 years). Boost dose (P < .001) and boost margin (P = .001) differed between groups. Adjusting for covariates, the PRT group exhibited superior long-term outcomes in global intelligence quotient (IQ), perceptual reasoning, and working memory compared with the XRT group (all P < .05). The XRT group exhibited a significant decline in global IQ, working memory, and processing speed (all P < .05). The PRT group exhibited stable scores over time in all domains with the exception of processing speed (P = .003). CONCLUSION To our knowledge, this is the first study to compare intellectual trajectories between pediatric patients treated for medulloblastoma with PRT versus those treated with XRT on comparable, contemporary protocols. PRT was associated with more favorable intellectual outcomes in most domains compared with XRT, although processing speed emerged as a vulnerable domain for both groups. This study provides the strongest evidence to date of an intellectual sparing advantage with PRT in the treatment of pediatric medulloblastoma.
AB - PURPOSE Proton radiotherapy (PRT) may lessen the neuropsychological risk traditionally associated with cranial radiotherapy for the treatment of pediatric brain tumors by reducing the dose to normal tissue compared with that of photon radiotherapy (XRT). We examined the change in intellectual scores over time in patients with pediatric medulloblastoma treated with craniospinal PRT versus XRT. METHODS Intelligence test scores were obtained for a sample of pediatric patients treated between 2007 and 2018 on the same medulloblastoma protocols that differed only in radiotherapy modality (PRT v XRT). Growth curve analyses compared change in scores over time since diagnosis between groups. RESULTS Longitudinal intelligence data from 79 patients (37 PRT, 42 XRT) were examined. Groups were similar on most demographic/clinical variables, including sex (67.1% male), age at diagnosis (mean, 8.6 years), craniospinal irradiation dose (median, 23.4 Gy), length of follow-up (mean, 4.3 years), and parental education (mean, 14.3 years). Boost dose (P < .001) and boost margin (P = .001) differed between groups. Adjusting for covariates, the PRT group exhibited superior long-term outcomes in global intelligence quotient (IQ), perceptual reasoning, and working memory compared with the XRT group (all P < .05). The XRT group exhibited a significant decline in global IQ, working memory, and processing speed (all P < .05). The PRT group exhibited stable scores over time in all domains with the exception of processing speed (P = .003). CONCLUSION To our knowledge, this is the first study to compare intellectual trajectories between pediatric patients treated for medulloblastoma with PRT versus those treated with XRT on comparable, contemporary protocols. PRT was associated with more favorable intellectual outcomes in most domains compared with XRT, although processing speed emerged as a vulnerable domain for both groups. This study provides the strongest evidence to date of an intellectual sparing advantage with PRT in the treatment of pediatric medulloblastoma.
UR - http://www.scopus.com/inward/record.url?scp=85078300215&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078300215&partnerID=8YFLogxK
U2 - 10.1200/JCO.19.01706
DO - 10.1200/JCO.19.01706
M3 - Article
C2 - 31774710
AN - SCOPUS:85078300215
VL - 38
SP - 454
EP - 461
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 5
ER -